Physician profile
Nancy Stranz
NPI 1144542382
$1,549.69
in general payments reported to CMS, 2019-2025
31 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $161 · 2021: $301 · 2022: $327 · 2023: $310 · 2024: $46.41 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.01 | 2019-2023 | Orilissa, Lo Loestrin Fe, Oriahnn |
| Aspira Women'S Health INC | $153.04 | 2021-2022 | |
| Evofem Biosciences, INC. | $127.07 | 2021-2022 | |
| Hologic Sales and Service, LLC | $109.92 | 2020-2025 | Myosure Tissue Removal Device, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Acessa Provu System |
| Daiichi Sankyo INC. | $81.05 | 2020-2023 | Injectafer |
| Organon LLC | $77.21 | 2022-2023 | Nexplanon |
| Exeltis, USA INC. | $75.46 | 2020-2025 | Slynd |
| Mayne Pharma Commercial LLC | $74.22 | 2022-2023 | |
| Coopersurgical, INC. | $57.26 | 2020-2025 | Paragard T 380a |
| Therapeuticsmd, INC. | $54.35 | 2019-2022 | |
| Astellas Pharma US INC | $48.34 | 2024-2025 | Veozah |
| Allergan, INC. | $47.73 | 2019 | |
| Merck Sharp & Dohme LLC | $42.59 | 2019-2020 | |
| Minerva Surgical, INC | $41.31 | 2020 | |
| Pfizer INC. | $38.77 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $36.45 | 2019 | |
| Millicent US INC | $24.08 | 2025 | Intrarosa, Femring |
| Supernus Pharmaceuticals, INC. | $19.67 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $19.67 | 2025 | Zurzuvae |
| Biohaven Pharmaceuticals, INC. | $19.63 | 2021 | |
| Gynesonics, INC. | $19.51 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Amgen INC. | $18.00 | 2021 | |
| Becton, Dickinson and Company | $17.94 | 2023 | Bd Onclarity |
| Roche Diagnostics Corporation | $16.81 | 2019 | |
| Shield Therapeutics INC | $14.86 | 2024 | |
| Vertical Pharmaceuticals, LLC | $13.98 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.15 | 2019 | |
| Dysis Medical, INC. | $12.92 | 2021 | |
| Novo Nordisk INC | $12.25 | 2020 | |
| Mylan Pharmaceuticals INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Stranz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.